Breaking News, Financial News

Financial Report: Merck

Pharma sales up 2%, hurt by Remicade settlement

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck   2Q Revenues: $12.3 billion (+1%) 2Q Earnings: $1.8 billion (-11%) YTD Revenues: $24.0 billion (+1%) YTD Earnings: $3.6 billion (+15%) Comments: Pharmaceutical sales were up 2% to $10.6 billion in the quarter. Singulair sales were $1.4 billion (+6%). Januvia sales were up 36% to $1.1 billion. Zetia sales were up 7% to $632 million. Janumet sales were 28% to $411 million. Gardasil sales were up 17% to $324 million. Remicade sales were down 38%, impacted by territories transferred to Jo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters